Immune-related Myocarditis Caused by PD-L1 Inhibitor Atezolizumab in Thymoma Treatment：Report of One Case

doi:10.12114/j.issn.1007-9572.2020.00.382

Abstract

Abstract: In recent years，a breakthrough has been made in cancer treatment by immune checkpoint inhibitors （ICIs）.However，with the extensive application of ICIs，reports of immune-related adverse event（irAE） associated with ICIs are increasing，among which immune-related myocarditis is rare but highly fatal.We reported a case of immune-related myocarditis after Atezolizumab treatment of thymoma，and conducted a literature review of the clinical features，possible pathogenesis，treatment and prognosis of this disease.

Key words: Myocarditis, Thymoma, Cancer, Immune checkpoint inhibitor, Immune-related adverse event, Atezolizumab

摘要： 近几年，免疫检查点抑制剂在肿瘤治疗方面取得突破性进展，随着临床应用的增多，免疫相关性不良事件（irAE）的报道也随之增多，其中免疫相关性心肌炎是一种罕见但病死率高的irAE。本文报道1例胸腺瘤患者使用Atezolizumab治疗后出现免疫相关性心肌炎，对免疫相关性心肌炎的临床特征、可能的发病机制、治疗与预后进行文献回顾。

关键词: 心肌炎, 胸腺瘤, 肿瘤, 免疫检查点抑制剂, 免疫相关性不良事件, Atezolizumab

LONG Lang,LUO Feng,WANG Li, et al. Immune-related Myocarditis Caused by PD-L1 Inhibitor Atezolizumab in Thymoma Treatment：Report of One Case　[J]. Chinese General Practice, 2021, 24(14): 1837-1840. DOI: 10.12114/j.issn.1007-9572.2020.00.382.
龙浪,罗锋,王力等. 程序性细胞死亡蛋白1配体抑制剂Atezolizumab引起免疫相关性心肌炎一例报道[J]. 中国全科医学, 2021, 24(14): 1837-1840. DOI: 10.12114/j.issn.1007-9572.2020.00.382.

References

［1］INMAN B A，LONGO T A，RAMALINGAM S，et al．Atezolizumab：a PD-L1-blocking antibody for bladder cancer［J］．Clin Cancer Res，2017，23（8）：1886-1890．
［2］KUMAR V，CHAUDHARY N，GARG M，et al．Corrigendum：current diagnosis and management of immune related adverse events （irAEs） induced by immune checkpoint inhibitor therapy［J］．Front Pharmacol，2017，8：311．DOI：10.3389/fphar.2017.00311.
［16］BRAVERMAN N，LIN P，MOEBIUS F F，et al．Mutations in the gene encoding 3 beta-hydroxysteroid-delta 8，delta 7-isomerose cause X-linked dominant Conradi-Hünermann syndrome［J］．Nat Genet，1999，22（3）：291-294．DOI：10.1038/10357.
［17］SARDIELLO M，ANNUNZIATA I，ROMA G，et al．Sulfatases and sulfatase modifying factors：an exclusive and promiscuous relationship［J］．Hum Mol Genet，2005，14（21）：3203-3217．DOI: 10.1093/hmg/ddi351.
［18］DANIELE A，PARENTI G，D'ADDIO M，et al．Biochemical characterization of arylsulfatase E and functional analysis of mutations found in patients with X-linked chondrodysplasia punctata［J］．Am J Hum Genet，1998，62（3）：562-572．DOI：10.1086/301746.
［19］BRUNETTI-PIERRI N，HUNTER J V，BOERKOEL C F.Gray matter heterotopias and brachytelephalangic chondrodysplasia punctata：a complication of hyperemesis gravidarum induced vitamin K deficiency？［J］．Am J Med Genet A，2007，143A（2）：200-204．DOI：10.1002/ajmg.a.31573.
［20］NINO M，MATOS-MIRANDA C，MAEDA M，et al．Clinical and molecular analysis of arylsulfatase E in patients with brachytelephalangic chondrodysplasia punctata［J］．Am J Med Genet A，2008，146A（8）：997-1008．DOI：10.1002/ajmg.a.32159.
［21］EASH D D，WEAVER D D，BRUNETTI-PIERRI N.Cervical spine stenosis and possible vitamin K deficiency embryopathy in an unusual case of chondrodysplasia punctata and an updated classification system［J］．Am J Med Genet A，2003，122A（1）：70-75．DOI：10.1002/ajmg.a.20242.
［22］MATOS-MIRANDA C，NIMMO G，WILLIAMS B，et al．A prospective study of brachytelephalangic chondrodysplasia punctata：identification of arylsulfatase E mutations，functional analysis of novel missense alleles，and determination of potential phenocopies［J］．Genet Med，2013，15（8）：650-657．DOI：10.1038/gim.2013.13.
［23］MOROTA N，IHARA S，OGIWARA H，et al．Surgical management of cervical spine deformity in chondrodysplasia punctata［J］．J Neurosurg Pediatr，2017，20（4）：378-387．DOI：10.3171/2017.5.PEDS16554.
［24］BOULET S，DIETERICH K，ALTHUSER M，et al．Brachytelephalangic chondrodysplasia punctata：prenatal diagnosis and postnatal outcome［J］．Fetal Diagn Ther，2010，28（3）：186-190．DOI：10.1159/000297289.
［25］WOLPOE M E，BRAVERMAN N，LIN S Y.Severe tracheobronchial stenosis in the X-linked recessive form of chondrodysplasia punctata［J］．Arch Otolaryngol Head Neck Surg，2004，130（12）：1423-1426．DOI：10.1001/archotol.130.12.1423.
［26］HERTZBERG B S，KLIEWER M A，DECKER M，et al．Antenatal ultrasonographic diagnosis of rhizomelic chondrodysplasia punctata［J］．J Ultrasound Med，1999，18（10）：715-718．DOI：10.7863/jum.1999.18.10.715.
［3］WANG D Y，SALEM J E，COHEN J V，et al．Fatal toxic effects associated with immune checkpoint inhibitors：a systematic review and meta-analysis［J］．JAMA Oncol，2018，4（12）：1721-1728．DOI：10.1001/jamaoncol.2018.3923.
［4］MAHMOOD S S，FRADLEY M G，COHEN J V，et al．Myocarditis in patients treated with immune checkpoint inhibitors［J］．J Am Coll Cardiol，2018，71（16）：1755-1764．
［5］CHEN Q，HUANG D S，ZHANG L W，et al．Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma［J］．Clin Toxicol （Phila），2018，56（7）：667-671．DOI：10.1080/15563650.2017.1401079.
［6］GRABIE N，GOTSMAN I，DACOSTA R，et al．Endothelial programmed death-1 ligand 1 （PD-L1） regulates CD8+ T-cell mediated injury in the heart［J］．Circulation，2007，116（18）：2062-2071．DOI：10.1161/CIRCULATIONAHA.107.709360.
［7］MATSON D R，ACCOLA M A，REHRAUER W M，et al．Fatal myocarditis following treatment with the PD-1 inhibitor nivolumab［J］．J Forensic Sci，2018，63（3）：954-957．
［8］TAJIRI K，AONUMA K，SEKINE I.Immune checkpoint inhibitor-related myocarditis［J］．Jpn J Clin Oncol，2018，48（1）：7-12．
［9］GANATRA S，NEILAN T G.Immune checkpoint inhibitor-associated myocarditis［J］．Oncologist，2018，23（8）：879-886．
［10］LIU S Y，HUANG W C，YEH H I，et al．Sequential blockade of PD-1 and PD-L1 causes fulminant cardiotoxicity-from case report to mouse model validation［J］．Cancers （Basel），2019，11（4）：E580．DOI：10.3390/cancers11040580.
［11］BRAHMER J R，LACCHETTI C，SCHNEIDER B J，et al．Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy：American Society of Clinical Oncology clinical practice guideline［J］．J Clin Oncol，2018，36（17）：1714-1768．DOI：10.1200/JCO.2017.77.6385.
［12］ESFAHANI K，BUHLAIGA N，THéBAULT P，et al．Alemtuzumab for immune-related myocarditis due to PD-1 therapy［J］．N Engl J Med，2019，380（24）：2375-2376．
［13］SALEM J E，ALLENBACH Y，VOZY A，et al．Abatacept for severe immune checkpoint inhibitor-associated myocarditis［J］．N Engl J Med，2019，380（24）：2377-2379．DOI：10.1056/NEJMc1901677.
［14］FAN Q Q，HU Y，YANG C Q，et al．Myocarditis following the use of different immune checkpoint inhibitor regimens：a real-world analysis of post-marketing surveillance data［J］．Int Immunopharmacol，2019，76：105866．DOI：10.1016/j.intimp.2019.105866.

[1]	LI Qianqian, CHEN Xunrui, ZHANG Wenying, YUAN Haihua, ZHANG Yanjie, JIANG Bin, LIU Feng. Demand and Influencing Factors for Community Health Services during Chemotherapy of Patients with Advanced Cancer [J]. Chinese General Practice, 2023, 26(33): 4173-4180.
[2]	ZHANG Dongli, SHEN Chong, ZHANG Weichuan, CHEN Haibin, ZHAO Jianjun. Efficacy and Safety of Programmed Death-1/Programmed Death-1 Ligand Inhibitors in the Treatment of Renal Cell Cancer: a Meta-analysis [J]. Chinese General Practice, 2023, 26(30): 3815-3822.
[3]	LI Jilei, LI Honglin, XU Yanchao, LIU Yanan, CHEN Mengli, SHAO Shuai, MA Chunzheng. Clinical Study on the Combination of Xiaotan Huayu Tongyi Granules, Channel Kaijie Pills and Chemotherapy in the Treatment of Esophageal Cancer [J]. Chinese General Practice, 2023, 26(30): 3759-3764.
[4]	ZHENG Yuling, ZHANG Yaling, LIU Huaimin, XU Yanchao, JIA Xiaolin, LI Junsai, HE Wenlong, TONG Xinduo, QIN Shanwen, ZHANG Lihan. Clinical Observation of Dingxiang Guanshitong Hanhua Pills Alone and Its Combination with Fugui Guanshitong Granules in the Treatment of Advanced Esophageal Cancer [J]. Chinese General Practice, 2023, 26(30): 3765-3771.
[5]	YAN Ke, WEI Wanyi, LI Shuguang, YAO Weinan, DONG Jing, WANG Xiaobin, ZHANG Xueyuan, YANG Jie, SHEN Wenbin, ZHU Shuchai. Effect of Consolidation Chemotherapy on Prognosis of StageⅡ-Ⅲ Esophageal Squamous Cell Carcinoma Patients Treated with Definitive Concurrent Chemotherapy and Radio-therapy [J]. Chinese General Practice, 2023, 26(30): 3772-3779.
[6]	YAN Ke, WEI Wanyi, DENG Wenzhao, SHEN Wenbin, LI Shuguang, DU Xingyu, ZHANG Xueyuan, YANG Jie, ZHU Shuchai. Long-term Prognosis Analysis and Influencing Factors of Concurrent Chemotherapy and Radio-therapy for Cervical and Upper Thoracic Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2023, 26(30): 3785-3790.
[7]	HU Jingyi, HONG Jing, GUO Xiaodong, ZHANG Xiaohong, MO Ning, ZHOU Xiaocui, YU Qin, ZHOU Minhua, SUN Yan, NI Liu, SHI Xiaoli, SU Xiaoqing, LI Yuqian. Efficacy of Community-involved Hospice Care for Patients with Advanced Cancer: a Meta-analysis [J]. Chinese General Practice, 2023, 26(28): 3573-3584.
[8]	DUAN Yuxia, LI Zhen, ZHANG Siqi, FANG Zhixue, QIN Yuelan. Effect of Patient Decision Aids in the Diagnosis and Treatment of Colorectal Cancer: a Systematic Review [J]. Chinese General Practice, 2023, 26(25): 3194-3201.
[9]	WANG Rui, WANG Xiaomei, PENG Guoqing, YU Huan, WANG Sihan, XIA Jin. Screening Assessment and Therapy Intervention of Cancer Cachexia in Adult Patients——Based on the Interpretation of Cancer Cachexia in Adult Patients: ESMO Clinical Practice Guidelines [J]. Chinese General Practice, 2023, 26(23): 2823-2829.
[10]	ZHANG Yanjing, SONG Xiaokun. Ideas for the Diagnosis and Treatment of Multisystem Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors [J]. Chinese General Practice, 2023, 26(23): 2930-2935.
[11]	CHEN Lulu, ZHANG Liping, LI Jingwen, DONG Wenjie, WU Xin'ai. Clinical Effect and Safety of PD-1 Inhibitors plus Fruquintinib as Later-line Treatment for Metastatic Colorectal Cancer [J]. Chinese General Practice, 2023, 26(18): 2262-2267.
[12]	SHEN Aomei, LU Qian, FU Xin, WEI Xiaoxia, BIAN Jingru, ZHANG Liyuan, QIANG Wanmin, PANG Dong. Constructing a Risk Prediction Model of Breast Cancer-related Lymphedema Based on a Meta-analysis of Prospective Cohort Studies [J]. Chinese General Practice, 2023, 26(17): 2078-2088.
[13]	CHANG Junpei, CHEN Lu, WU Tong, ZHAO Xiaoli, DUAN Fangfang, LIU Danna, KONG Tiandong. Occurrence and Treatment of Endocrinologic Adverse Reactions Associated with Immune Checkpoint Inhibitors: a Single-center Real-world Study [J]. Chinese General Practice, 2023, 26(17): 2095-2101.
[14]	National Center of Gerontology, Electrocardiology and Cardiac Function Branch of Chinese Geriatric Society, Imaging Group of Cardiovascular Department, Beijing Medical Association, Chinese Medical and Health Culture Association Cardiovascular Health and Science Sports Branch of China Health Culture Association. Expert Consensus for Management of Myocardial Injury, Myocarditis, and Post-infection Condition with Coronavirus Disease 2019 (Second Edition) [J]. Chinese General Practice, 2023, 26(14): 1692-1702.
[15]	YU Rong, DONG Weiguo, TIAN Shan, WANG Ting. Clinical Research Progress on Carcinogenesis of Different Pathological Types of Colorectal Polyps [J]. Chinese General Practice, 2023, 26(14): 1790-1794.